Data as of:
brimindinvest.com / compare / xlv-vs-vhtLIVE
XLV
Health Care Select Sector SPDR Fund · ETF
$168.39
-4.15% this month
VERSUS
COMPARE
VHT
Vanguard Health Care ETF · ETF
$315.85
-4.14% this month
Comparison scoreboard
XLV LEADS 4/5
Exp. Ratioi
XLV 0.08%
VHT 0.09%
1Y Returni
XLV +24.63%
VHT +25.23%
Div. Yieldi
XLV 1.49%
VHT 1.48%
AUMi
XLV $43.91B
VHT $22.04B
Betai
XLV 0.55
VHT 0.59
Metrics last refreshed: 9/19/2026
Quick take

XLV vs VHT Stock Comparison: AI Score, Valuation, Performance and Upside

ShareXLinkedInRedditFacebookWhatsApp

XLV and VHT both target health care sector exposure but take different paths to get there — XLV via the Health Care Select Sector Index, and VHT via the MSCI US Investable Market Health Care Index. The practical differences come down to issuer, cost structure, and the specific index rules each fund follows, since both are pursuing a similar investment outcome.

XLV vs VHT is largely a question of which issuer and index methodology you trust more for health care sector exposure — the underlying investment case is similar, so cost, liquidity, and tracking precision tend to be the deciding factors.

Live analysis · updated 9/19/2026

XLV holds the edge across 4 of 5 key metrics in this comparison. VHT has delivered stronger 1-year price return (+25.23% vs +24.63% for XLV).

Normalized 1Y performance
XLV
VHT
Recent returns
XLV
VHT
Who should consider this stock?
XLV may suit investors who:
  • want concentrated large-cap health care exposure with deep liquidity
  • prefer State Street's approach and fund lineup
  • value deepest liquidity of any health care sector ETF
  • are comfortable with exposed to drug-pricing and regulatory policy risk
VHT may suit investors who:
  • want broader health care exposure including more biotech names
  • prefer Vanguard's approach and fund lineup
  • value lower expense ratio than the SPDR health care fund
  • are comfortable with thinner liquidity than XLV
Performance & AI score
Performance & AI score
MetricXLVVHT
ETF scorei74.076.0
Latest closei$168.39$315.85
1M returni-4.15%-4.14%
6M returni+16.86%+18.25%
1Y returni+24.63%+25.23%

The ETF score weights long-term returns and risk-adjusted performance most heavily, but still rewards low expense ratios, larger fund size, and broader diversification — so it can favor low-cost, broad, mega-cap funds over smaller thematic or actively-managed funds even when the latter have delivered stronger returns.

$10,000 invested — hypothetical growth (dividends reinvested)

How much would $10,000 be worth today if invested at the start of each period, with all dividends reinvested?

$10,000 invested — hypothetical growth (dividends reinvested)
PeriodXLVVHT
1Y ago$12.68K (+26.8%)
started 2025-09-18
$12.74K (+27.4%)
started 2025-09-18
5Y ago$15.09K (+50.9%)
started 2021-09-20
$14.36K (+43.6%)
started 2021-09-20
10Y ago$32.96K (+229.6%)
started 2016-09-19
$32.32K (+223.2%)
started 2016-09-19

Hypothetical — past performance does not guarantee future results.

Fund characteristics
Fund characteristics
MetricXLVVHT
Expense ratioi0.08%0.09%
Total assets (AUM)i$43.91B$22.04B
Dividend yieldi1.49%1.48%
Trailing P/Ei30.0929.62
Betai0.550.59
52-week change24.63%25.23%
Risk & fund metrics
Risk & fund metrics
MetricXLVVHT
1Y returni+24.63%+25.23%
6M returni+16.86%+18.25%
1M returni-4.15%-4.14%
1Y Sharpe ratio1.171.24
Betai0.550.59
Dividend yieldi1.49%1.48%
5Y CAGR+6.78%+5.88%
Correlation

Over the past year, XLV and VHT have moved strongly in the same direction (correlation of 0.99), based on daily returns.

1Y
0.99
-1.0+1.0
5Y
0.99
-1.0+1.0
10Y
0.99
-1.0+1.0
Drawdown & downside risk

Lower drawdown and smaller single-period drops generally indicate a smoother ride, though they do not guarantee lower future risk.

1Y risk snapshot
XLV max drawdowni10.47%
VHT max drawdowni10.40%
XLV max wkly dropi4.68%
VHT max wkly dropi4.52%
5Y risk snapshot
XLV max drawdowni17.11%
VHT max drawdowni17.71%
XLV max wkly dropi8.36%
VHT max wkly dropi8.55%
10Y risk snapshot
XLV max drawdowni28.40%
VHT max drawdowni28.85%
XLV max wkly dropi13.20%
VHT max wkly dropi14.40%
Performance metrics by period
Performance metrics by period
PeriodMetricXLVVHT
1YGrowthi+24.63%+25.23%
CAGRi+24.65%+25.25%
Volatilityi16.13%15.51%
Sharpe ratioi1.171.24
Sortino ratioi1.952.06
Max drawdowni10.47%10.40%
Current drawdowni4.15%4.14%
Avg drawdowni3.29%3.20%
Ulcer Indexi4.46%4.28%
Max daily dropi2.52%2.19%
Max wkly dropi4.68%4.52%
5YGrowthi+38.74%+33.02%
CAGRi+6.78%+5.88%
Volatilityi15.19%15.39%
Sharpe ratioi0.210.16
Sortino ratioi0.300.22
Max drawdowni17.11%17.71%
Current drawdowni4.15%4.14%
Avg drawdowni5.82%6.40%
Ulcer Indexi7.08%7.64%
Max daily dropi5.48%5.47%
Max wkly dropi8.36%8.55%
10YGrowthi+176.00%+175.62%
CAGRi+10.69%+10.68%
Volatilityi16.73%17.07%
Sharpe ratioi0.420.42
Sortino ratioi0.600.59
Max drawdowni28.40%28.85%
Current drawdowni4.15%4.14%
Avg drawdowni4.65%4.93%
Ulcer Indexi6.12%6.45%
Max daily dropi9.86%11.05%
Max wkly dropi13.20%14.40%
AI Prediction Signali
Members only
Next 5 trading days
XLV
+2.8%BUY
VHT
+1.1%HOLD
Next 30 trading days
XLV
+6.4%BUY
VHT
+3.2%HOLD

Sign up to unlock AI price predictions

ML model trained on historical prices · 14-day free trial · No credit card required
Fund overview
Fund overview
CategoryXLVVHT
Fund nameState Street Health Care Select Sector SPDR ETFVanguard Health Care Index Fund ETF Shares
TypeETFETF
Expense ratioi0.08%0.09%
Total assets (AUM)i$43.91B$22.04B
Dividend yieldi1.49%1.48%
XLV strengths
  • Deepest liquidity of any health care sector ETF
  • Diversified across pharma, insurers, and device makers
  • Defensive sector that often holds up in downturns
VHT strengths
  • Lower expense ratio than the SPDR health care fund
  • More biotech and small-cap health exposure than XLV
  • Vanguard's indexing efficiency
Risks to watch — XLV
  • Exposed to drug-pricing and regulatory policy risk
  • Patent-cliff and FDA-decision headline risk for individual holdings
  • Concentration in a handful of pharma giants
Risks to watch — VHT
  • Thinner liquidity than XLV
  • More biotech exposure adds binary clinical-trial risk
  • Regulatory and drug-pricing risk applies sector-wide
Frequently asked questions
Neither XLV nor VHT is universally "better" — XLV is built for concentrated large-cap health care exposure with deep liquidity, while VHT is built for broader health care exposure including more biotech names. Investors should pick based on which exposure and cost structure fits their own portfolio goals rather than assuming one strictly dominates the other.
Free public comparison

Want deeper AI forecasts?

This comparison page is public and free forever. Subscribers can unlock saved watchlists, full AI rankings, detailed forecasts, and interactive analysis tools.

Related comparisons
More comparisons
Browse all 1,000 comparisons
ShareXLinkedInRedditFacebookWhatsApp